What are the benefits of using bivalirudin during coronary angioplasty?
Bivalirudin, when compared to unfractionated heparin, has been found to reduce bleeding complications among patients undergoing coronary angioplasty, as demonstrated by a meta-analysis of randomised trials. Additionally, bivalirudin may provide improved outcomes in terms of major adverse cardiac events, such as myocardial infarction, compared to heparin.